Skip to main content
Premium Trial:

Request an Annual Quote

Frances Heller, Ronald Marler, Mark Wdowik

Exelixis has appointed Frances Heller as executive vice president of business development, the company said last week.
Heller joins Exelixis from the Novartis Institutes for Biomedical Research, the global research organization for Novartis AG, where she was head of strategic alliances. Previously, she served as vice president of corporate development and legal affairs at Signature BioScience; and corporate and intellectual property counsel for Celera Genomics.
Heller received a JD from the Golden Gate University School of Law and an MA in biology from American University.

CSU Ventures, the non-profit business-development arm of Colorado State University, said last week that Ronald Marler has been appointed as CEO.
Marler is currently a board member of CSU Ventures. In his new role, he will work closely with Mark Wdowik, who has served as inaugural CEO of the corporation since February 2007. Wdowik will now be responsible for launching a CSU for-profit seed investment fund, which will invest in CSU start-ups and key research partners.
Marler has more than 30 years of experience in the pharmaceutical research and product development fields, CSU said. He is currently a senior administrator at Mayo Clinic Arizona, and CSO and board member of Bridge Laboratories. He received a BS, DVM, and PhD from Kansas State University.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.